[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

HUE065746T2 - Készítmények és eljárások aktív mycobacterium tuberculosis fertõzés kezelésére - Google Patents

Készítmények és eljárások aktív mycobacterium tuberculosis fertõzés kezelésére

Info

Publication number
HUE065746T2
HUE065746T2 HUE13836324A HUE13836324A HUE065746T2 HU E065746 T2 HUE065746 T2 HU E065746T2 HU E13836324 A HUE13836324 A HU E13836324A HU E13836324 A HUE13836324 A HU E13836324A HU E065746 T2 HUE065746 T2 HU E065746T2
Authority
HU
Hungary
Prior art keywords
compositions
treating
methods
mycobacterium tuberculosis
tuberculosis infection
Prior art date
Application number
HUE13836324A
Other languages
English (en)
Inventor
Steven Reed
Rhea Coler
Original Assignee
Access To Advanced Health Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Access To Advanced Health Inst filed Critical Access To Advanced Health Inst
Publication of HUE065746T2 publication Critical patent/HUE065746T2/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
HUE13836324A 2012-08-03 2013-08-02 Készítmények és eljárások aktív mycobacterium tuberculosis fertõzés kezelésére HUE065746T2 (hu)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261679612P 2012-08-03 2012-08-03
US201361791213P 2013-03-15 2013-03-15

Publications (1)

Publication Number Publication Date
HUE065746T2 true HUE065746T2 (hu) 2024-06-28

Family

ID=50278593

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE13836324A HUE065746T2 (hu) 2012-08-03 2013-08-02 Készítmények és eljárások aktív mycobacterium tuberculosis fertõzés kezelésére

Country Status (13)

Country Link
US (2) US20150182612A1 (hu)
EP (2) EP4299138A3 (hu)
JP (1) JP2015525784A (hu)
CN (1) CN104812404A (hu)
BR (1) BR112015002483A2 (hu)
ES (1) ES2969734T3 (hu)
HR (1) HRP20240164T1 (hu)
HU (1) HUE065746T2 (hu)
MX (1) MX2015001557A (hu)
PT (1) PT2879701T (hu)
RU (1) RU2659149C2 (hu)
WO (1) WO2014042780A1 (hu)
ZA (2) ZA201501242B (hu)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3024313A1 (en) * 2016-05-21 2017-11-30 Infectious Disease Research Institute Compositions and methods for treating secondary tuberculosis and nontuberculous mycobacterium infections
GB201909953D0 (en) * 2019-07-11 2019-08-28 Sec Dep For Environment Food And Rural Affairs Acting Through The Animal And Plant Health Agency Diagnostic reagents
US11679163B2 (en) 2019-09-20 2023-06-20 Hdt Bio Corp. Compositions and methods for delivery of RNA
EP4126021A1 (en) 2020-03-23 2023-02-08 HDT Bio Corp. Compositions and methods for delivery of rna
JP2024501949A (ja) 2020-12-23 2024-01-17 アクセス ツー アドバンスト ヘルス インスティチュート ソラネソールワクチンアジュバント及びその調製方法

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235877A (en) 1979-06-27 1980-11-25 Merck & Co., Inc. Liposome particle containing viral or bacterial antigenic subunit
US4554101A (en) 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
US4866034A (en) 1982-05-26 1989-09-12 Ribi Immunochem Research Inc. Refined detoxified endotoxin
US4436727A (en) 1982-05-26 1984-03-13 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
US4751180A (en) 1985-03-28 1988-06-14 Chiron Corporation Expression using fused genes providing for protein product
US4935233A (en) 1985-12-02 1990-06-19 G. D. Searle And Company Covalently linked polypeptide cell modulators
US4877611A (en) 1986-04-15 1989-10-31 Ribi Immunochem Research Inc. Vaccine containing tumor antigens and adjuvants
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
US5725871A (en) 1989-08-18 1998-03-10 Danbiosyst Uk Limited Drug delivery compositions comprising lysophosphoglycerolipid
US5707644A (en) 1989-11-04 1998-01-13 Danbiosyst Uk Limited Small particle compositions for intranasal drug delivery
US5466468A (en) 1990-04-03 1995-11-14 Ciba-Geigy Corporation Parenterally administrable liposome formulation comprising synthetic lipids
SE466259B (sv) 1990-05-31 1992-01-20 Arne Forsgren Protein d - ett igd-bindande protein fraan haemophilus influenzae, samt anvaendning av detta foer analys, vacciner och uppreningsaendamaal
US5399363A (en) 1991-01-25 1995-03-21 Eastman Kodak Company Surface modified anticancer nanoparticles
US5756353A (en) 1991-12-17 1998-05-26 The Regents Of The University Of California Expression of cloned genes in the lung by aerosol-and liposome-based delivery
EP0641192B1 (en) 1992-05-18 1997-07-23 Minnesota Mining And Manufacturing Company Transmucosal drug delivery device
US5750110A (en) 1992-06-25 1998-05-12 Smithkline Beecham Biologicals, S.A Vaccine composition containing adjuvants
US5543158A (en) 1993-07-23 1996-08-06 Massachusetts Institute Of Technology Biodegradable injectable nanoparticles
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
JP3468773B2 (ja) 1994-07-15 2003-11-17 ザ ユニバーシティ オブ アイオワ リサーチ ファウンデーション 免疫調節オリゴヌクレオチド
IE80468B1 (en) 1995-04-04 1998-07-29 Elan Corp Plc Controlled release biodegradable nanoparticles containing insulin
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
US5856462A (en) 1996-09-10 1999-01-05 Hybridon Incorporated Oligonucleotides having modified CpG dinucleosides
GB9727262D0 (en) 1997-12-24 1998-02-25 Smithkline Beecham Biolog Vaccine
AU746163B2 (en) 1998-04-09 2002-04-18 Smithkline Beecham Biologicals (Sa) Adjuvant compositions
EP1104306B1 (en) 1998-08-10 2006-01-11 Antigenics Inc. Compositions of cpg and saponin adjuvants and methods of use thereof
US7472098B2 (en) 2000-02-14 2008-12-30 Ubs Financial Services, Inc. System and method for execution of trades made pursuant to stock option and purchase plans
RU2262950C2 (ru) * 2001-03-23 2005-10-27 Каунсил Оф Сайентифик Энд Индастриал Рисерч Способ получения вакцины для лечения туберкулеза и других внутриклеточных инфекционных заболеваний и вакцина, полученная по названному способу
GB0125535D0 (en) * 2001-10-24 2001-12-12 Microbiological Res Authority Mycobacterial genes down-regulated during latency
PL2426141T3 (pl) * 2005-04-29 2015-02-27 Glaxosmithkline Biologicals Sa Sposób profilaktyki lub leczenia zakażenia m. tuberculosis
EP1991213A2 (en) * 2006-02-08 2008-11-19 Fasgen, Inc. Anti-mycobacterial formulation comprising octanesulphonylacetamide (osa), nonanesulphonylacetamide (nsa) and decanesulphonylacetamide (dsa)
ES2673046T3 (es) 2006-09-26 2018-06-19 Infectious Disease Research Institute Composición de vacuna que contiene un adyuvante sintético
US8486414B2 (en) * 2007-04-04 2013-07-16 Infectious Disease Research Institute Immunogenic compositions comprising Mycobacterium tuberculosis polypeptides and fusions thereof
WO2010010178A1 (en) * 2008-07-25 2010-01-28 Glaxosmithkline Biologicals S.A The tuberculosis rv2707c protein, compositions and uses thereof
US8658350B2 (en) * 2008-09-22 2014-02-25 Oregon Health & Science University Methods for detecting Mycobacterium tuberculosis disease
GB201008512D0 (en) * 2010-05-21 2010-07-07 Health Prot Agency Mycobacterial antigen composition
EP2618838A1 (en) * 2010-09-20 2013-07-31 Crucell Holland B.V. Therapeutic vaccination against active tuberculosis

Also Published As

Publication number Publication date
EP2879701B1 (en) 2023-11-15
EP4299138A3 (en) 2024-08-14
EP2879701A1 (en) 2015-06-10
PT2879701T (pt) 2024-02-12
US11369672B2 (en) 2022-06-28
ZA201702091B (en) 2018-12-19
EP2879701A4 (en) 2016-01-20
WO2014042780A1 (en) 2014-03-20
MX2015001557A (es) 2015-10-08
ES2969734T3 (es) 2024-05-22
US20150182612A1 (en) 2015-07-02
EP4299138A2 (en) 2024-01-03
JP2015525784A (ja) 2015-09-07
HRP20240164T1 (hr) 2024-04-12
ZA201501242B (en) 2017-08-30
RU2659149C2 (ru) 2018-06-28
US20200038498A1 (en) 2020-02-06
RU2015107435A (ru) 2016-09-27
BR112015002483A2 (pt) 2017-11-07
CN104812404A (zh) 2015-07-29

Similar Documents

Publication Publication Date Title
IL284506B (en) Biological markers and signatures for diagnosing infections and methods for their use
HK1214521A1 (zh) 用於治療蛋白質病的組合物和方法
EP2869297A4 (en) ACTIVE NOISE REDUCTION DEVICE AND ACTIVE NOISE REDUCTION METHOD
HK1200491A1 (en) Methods and compositions for regulating hiv infection hiv
AP2014007835A0 (en) Oxazolidin-2-one compounds and uses thereof as P13KS inhibitors
HK1251796A1 (zh) 治療糖尿病的方法和組合物
HK1209633A1 (en) Compositions and methods for treating diabetes
GB2509397B (en) Rigid-stem active method and system
ZA201702091B (en) Compositions and methods for treating an active mycobacterium tuberculosis infection
EP2869821A4 (en) COMPOSITIONS AND METHODS FOR TREATING AND INHIBITING VIRAL INFECTIONS
EP2802353A4 (en) COMPOSITIONS AND METHOD FOR THE TREATMENT OF VIRUS INFECTIONS
HK1210163A1 (en) Compositions and methods for treating or preventing pneumovirus infection and associated diseases
HK1208598A1 (en) Methods and compositions for treating pain
EP2632460A4 (en) COMPOSITIONS AND METHOD FOR THE TREATMENT OF TUBERCULOSIS
EP2873729A4 (en) MICROSTRUCTURE FOR TRAPPING AND RELEASING MICROORGANISMS
EP2800405A4 (en) METHOD AND DEVICE FOR SECURE PROCESSING OF SHORT MESSAGES
ZA201500254B (en) Status of tuberculosis infection in an individual
HK1206238A1 (en) Composition for preventing and treating aids and preparation method thereof
EP2928460A4 (en) METHODS FOR THE PREVENTION AND TREATMENT OF INFLAMMATORY SKIN DISEASES
PL2845275T3 (pl) Urządzenie antystatyczne i przynależny sposób sterowania działaniem
EP2907890A4 (en) PVD TREATMENT PROCESS AND PVD TREATMENT DEVICE
PT2838903T (pt) Métodos e composições para tratamento de infeções virais
EP2854427A4 (en) METHOD AND DEVICE FOR PROCESSING SESSION
AU2012902982A0 (en) Compositions and methods for the treatment of tuberculosis
AU2012905097A0 (en) Agents and methods for inhibiting virus infection